Title: Class III ß-Tubulin Isotope Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Docetaxel
Authors: GALMARINI Carlos M.TREILLEUX IsabelleCARDOSO FatimaBERNARD-MARTY ChantalDURBECQ VirginieGANCBERG DavidBISSERY Marie-ChristinePAESMANS MarianneLARSIMONT DenisPICCART Martine J.DI LEO AngeloDUMONTET Charles
Citation: CLINICAL CANCER RESEARCH vol. 14 no. 14 p. 4511-4516
Publisher: AMER ASSOC CANCER RESEARCH
Publication Year: 2008
JRC N°: JRC47227
ISSN: 1078-0432
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC47227
DOI: 10.1158/1078-0432.CCR-07-474
Type: Articles in Journals
Abstract: Evaluate microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agent docetaxel or doxorubicin chemotherapy. Expression of total alpha- or beta-tubulin, classes II to IV beta-tubulin isotypes, and tau protein was evaluated by immunohistochemistry on the primary breast cancer. Patients with "high" expression of class III beta-tubulin isotype had a higher probability of response to docetaxel than to doxorubicin treatment. This study suggests that the superiority of docetaxel over doxorubicin seems restricted to the subgroup of patients with "high" expression of class III beta-tubulin isotype.
JRC Institute:Institute for Reference Materials and Measurements

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.